Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia

Akihisa Yumoto, Fukushima Kusano Kengo, Kazufumi Nakamura, Katsushi Hashimoto, Motokuni Aoki, Ryuichi Morishita, Yasufumi Kaneda, Tohru Ohe

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined the anti-arrhythmic effect of HGF gene therapy in rat acute and old myocardial infarction models. Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemagglutinating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the myocardium fourteen days before programmed pacing. Ventricular fibrillation (VF) was induced by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF gene therapy (P <0.01). Histological analyses revealed that the number of vessels in the ischemic border zone was greatly increased after HGF gene injection. These findings revealed that HGF gene therapy has an anti-arrhythmic effect after myocardial ischemia. Copyright

Original languageEnglish
Pages (from-to)73-78
Number of pages6
JournalActa Medica Okayama
Volume59
Issue number3
Publication statusPublished - Jun 2005

Fingerprint

Gene therapy
Hepatocyte Growth Factor
Genetic Therapy
Myocardial Ischemia
Cardiac Arrhythmias
Animals
Animal Models
Ventricular Fibrillation
Anti-Arrhythmia Agents
Genes
Sendai virus
Viruses
Liposomes
Ligation
Rats
Coronary Vessels
Myocardium
Myocardial Infarction
Injections

Keywords

  • HGF (hepatocyte growth factor)
  • HVJ (hemagglutinating virus of Japan)
  • Ischemia
  • Ventricular arrhythmia

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Yumoto, A., Kengo, F. K., Nakamura, K., Hashimoto, K., Aoki, M., Morishita, R., ... Ohe, T. (2005). Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia. Acta Medica Okayama, 59(3), 73-78.

Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia. / Yumoto, Akihisa; Kengo, Fukushima Kusano; Nakamura, Kazufumi; Hashimoto, Katsushi; Aoki, Motokuni; Morishita, Ryuichi; Kaneda, Yasufumi; Ohe, Tohru.

In: Acta Medica Okayama, Vol. 59, No. 3, 06.2005, p. 73-78.

Research output: Contribution to journalArticle

Yumoto, A, Kengo, FK, Nakamura, K, Hashimoto, K, Aoki, M, Morishita, R, Kaneda, Y & Ohe, T 2005, 'Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia', Acta Medica Okayama, vol. 59, no. 3, pp. 73-78.
Yumoto, Akihisa ; Kengo, Fukushima Kusano ; Nakamura, Kazufumi ; Hashimoto, Katsushi ; Aoki, Motokuni ; Morishita, Ryuichi ; Kaneda, Yasufumi ; Ohe, Tohru. / Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia. In: Acta Medica Okayama. 2005 ; Vol. 59, No. 3. pp. 73-78.
@article{06bc5452e52341a59c285fa114efc14e,
title = "Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia",
abstract = "It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined the anti-arrhythmic effect of HGF gene therapy in rat acute and old myocardial infarction models. Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemagglutinating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the myocardium fourteen days before programmed pacing. Ventricular fibrillation (VF) was induced by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF gene therapy (P <0.01). Histological analyses revealed that the number of vessels in the ischemic border zone was greatly increased after HGF gene injection. These findings revealed that HGF gene therapy has an anti-arrhythmic effect after myocardial ischemia. Copyright",
keywords = "HGF (hepatocyte growth factor), HVJ (hemagglutinating virus of Japan), Ischemia, Ventricular arrhythmia",
author = "Akihisa Yumoto and Kengo, {Fukushima Kusano} and Kazufumi Nakamura and Katsushi Hashimoto and Motokuni Aoki and Ryuichi Morishita and Yasufumi Kaneda and Tohru Ohe",
year = "2005",
month = "6",
language = "English",
volume = "59",
pages = "73--78",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "3",

}

TY - JOUR

T1 - Hepatocyte growth factor gene therapy reduces ventricular arrhythmia in animal models of myocardial ischemia

AU - Yumoto, Akihisa

AU - Kengo, Fukushima Kusano

AU - Nakamura, Kazufumi

AU - Hashimoto, Katsushi

AU - Aoki, Motokuni

AU - Morishita, Ryuichi

AU - Kaneda, Yasufumi

AU - Ohe, Tohru

PY - 2005/6

Y1 - 2005/6

N2 - It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined the anti-arrhythmic effect of HGF gene therapy in rat acute and old myocardial infarction models. Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemagglutinating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the myocardium fourteen days before programmed pacing. Ventricular fibrillation (VF) was induced by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF gene therapy (P <0.01). Histological analyses revealed that the number of vessels in the ischemic border zone was greatly increased after HGF gene injection. These findings revealed that HGF gene therapy has an anti-arrhythmic effect after myocardial ischemia. Copyright

AB - It was recently reported that gene therapy using hepatocyte growth factor (HGF) has the potential to preserve cardiac function after myocardial ischemia. We speculated that this HGF gene therapy could also prevent ventricular arrhythmia. To investigate this possibility, we examined the anti-arrhythmic effect of HGF gene therapy in rat acute and old myocardial infarction models. Myocardial ischemia was induced by ligation of the left descending coronary artery. Hemagglutinating virus of Japan (HVJ)-coated liposome containing HGF genes were injected directly into the myocardium fourteen days before programmed pacing. Ventricular fibrillation (VF) was induced by programmed pacing. The VF duration was reduced and the VF threshold increased after HGF gene therapy (P <0.01). Histological analyses revealed that the number of vessels in the ischemic border zone was greatly increased after HGF gene injection. These findings revealed that HGF gene therapy has an anti-arrhythmic effect after myocardial ischemia. Copyright

KW - HGF (hepatocyte growth factor)

KW - HVJ (hemagglutinating virus of Japan)

KW - Ischemia

KW - Ventricular arrhythmia

UR - http://www.scopus.com/inward/record.url?scp=21644476821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644476821&partnerID=8YFLogxK

M3 - Article

C2 - 16049559

AN - SCOPUS:21644476821

VL - 59

SP - 73

EP - 78

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 3

ER -